London, Feb. 16, 2021 (AltAfrica)-Russia’s Sputnik V vaccine is has submitted documentation to South Africa’s local medicines regulator SAHPRA for registration and emergency authorization ministry said the manufacturers of Russia’s Sputnik V vaccine had .

South Africa’s health ministry said it was “continuously engaging” with the manufacturers of Sputnik V vaccine and that it had signed a non-disclosure agreement with China’s Sinopharm the manufacturer of the vaccine to receive more information about its Sputnik V vaccine.

READ ALSO: BRITISH COMPANY PAYS $9.7M TO VICTIMS OF RAPE, RIGHTS ABUSES IN MALAWI, KENYA

It added that scientists were conducting detailed analyses on the vaccine following concerns about the effects of its Ad5 component on communities with a high prevalence of HIV.

Russia’s Sputnik V vaccine makers seek to register the shot for use with South Africa’s health products regulator https://t.co/jhVeeu0kro

— Bloomberg (@business) February 16, 2021

South Africa has one of the highest HIV burdens globally.

Meanwhile, Reuters reports that South Africa plans to share 1 million AstraZeneca COVID-19 vaccine doses with other African countries, a senior official said, as a medical association said the first shots from rival Johnson & Johnson could arrive on Tuesday

The country paused the rollout of AstraZeneca doses this month, after preliminary trial data showed they offered minimal protection against mild to moderate illness from the country’s dominant coronavirus variant.

It has been consulting with scientists about what to do with the AstraZeneca vaccine, switching to a plan to start inoculating healthcare workers with J&J’s alternative in a research study. The South African Medical Association (SAMA) said if the first shots arrived on Tuesday as expected, then vaccinations could start on Wednesday.

Eighty thousand J&J shots are expected initially, and up to 500,000 health workers could be immunised in total in the study.

SAMA chairwoman Angelique Coetzee said vaccinations would happen at hospitals in each of the country’s nine provinces. Roughly two-thirds of the doses would go to public-sector health workers, and one-third to those in the private sector.

Anban Pillay, deputy director-general at the Department of Health, said South Africa planned to share the 1 million AstraZeneca doses it received at the start of the month from the Serum Institute of India via the African Union (AU).

“The doses are going to be shared with countries on the continent … via the AU,” Pillay told Reuters, adding that the government would look to recover money spent on the AstraZeneca vaccine but was still finalising how to do that.

He said it was not true that South Africa had asked the Serum Institute to take back the doses, as reported by Indian newspaper The Economic Times.

The AU’s disease control body said last week it was not “walking away” from AstraZeneca’s vaccine but would target its use in countries that have not reported cases of the more contagious 501Y.V2 variant first identified in South Africa late last year.

The AU said six countries other than South Africa had confirmed the variant was circulating, but there are concerns it has spread elsewhere.

AstraZeneca says it believes its two-dose vaccine protects against severe COVID-19 and that it has started adapting it to be more effective against the 501Y.V2 variant. J&J’s vaccine is administered in a single shot, an advantage given how complex a logistical exercise it will be for the government to reach its target of vaccinating 40 million people.